Cantargia
1.295
SEK
-2.04 %
1,301 following
CANTA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-2.04%
-18.24%
-23.01%
-23.37%
-55.77%
-68.8%
-91.11%
-89.96%
-81.68%
Cantargia operates in the pharmaceutical industry and focuses on the development of treatments for cancer and inflammatory diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Cantargia was founded in 2004 and is headquartered in Lund, Sweden.
Read moreMarket cap
321.95M SEK
Turnover
710.31K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
13/5
2025
Interim report Q1'25
15/5
2025
General meeting '25
21/8
2025
Interim report Q2'25
All
Webcasts
Press releases
3rd party
ShowingAll content types
Cantargia appoints Morten Lind Jensen as Chief Medical Officer
Cantargia publicerar ett abstrakt om samtidig antitumör-aktivitet och minskning av cellgifts-inducerad neuropati med nadunolimab
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Cantargia publishes an abstract on parallel anti-tumor activity and reduction of chemotherapy-induced neuropathy with nadunolimab
Cantargia presenterar lovande prekliniska resultat kring IL1RAP-ADC vid AACR 2025
Cantargia presents promising preclinical results on a novel IL1RAP-targeting antibody-drug conjugate at AACR 2025.
Finansinspektionen: Flaggningsmeddelande i CANTARGIA AB
Cantargia deltar på Van Lanschot Kempens Life Sciences Conference
Cantargia to Participate at Van Lanschot Kempen’s Life Sciences Conference
Första patienten rekryterad i Cantargias leukemistudie med nadunolimab
First patient enrolled in Cantargia’s leukemia study with nadunolimab
Cantargias TRIFOUR fas II-studie som undersöker nadunolimab i trippelnegativ bröstcancer fullt rekryterad
Cantargia’s TRIFOUR phase 2 study investigating nadunolimab in triple negative breast cancer fully recruited
Cantargia medverkar på H.C. Wainwrights Annual Autoimmune & Inflammatory Virtual Conference
Cantargia to Participate at H.C. Wainwright’s Annual Autoimmune & Inflammatory Virtual Conference
Cantargia meddelar lovande fas I-resultat från CAN10:s första grupp med multipel dos, samt feedback från FDA och kliniska experter
Cantargia reports promising CAN10 phase 1 data from first multiple dose cohort, and FDA and Key Opinion Leader feedback
Analysguiden: ANALYS Cantargia: På väg mot licensaffär
Redeye: Cantargia Q4 2024 - Focus on Business Development
